Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Identifieur interne : 003385 ( Main/Exploration ); précédent : 003384; suivant : 003386Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Auteurs : S. Loi [Belgique] ; S. Michiels [France] ; R. Salgado [Belgique] ; N. Sirtaine [Belgique] ; V. Jose [Belgique] ; D. Fumagalli [Belgique] ; P-L Kellokumpu-Lehtinen ; P. Bono ; V. Kataja [Finlande] ; C. Desmedt [Belgique] ; M J Piccart [Belgique] ; S. Loibl ; C. Denkert [Allemagne] ; M J Smyth [Australie] ; H. Joensuu ; C. Sotiriou [Belgique]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (usage thérapeutique), Biomarqueurs pharmacologiques (analyse), Femelle, Finlande, Humains, Lymphocytes TIL (anatomopathologie), Marqueurs biologiques tumoraux (analyse), Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Traitement médicamenteux adjuvant, Trastuzumab, Tumeurs du sein triple-négatives (anatomopathologie), Tumeurs du sein triple-négatives (diagnostic), Tumeurs du sein triple-négatives (immunologie), Tumeurs du sein triple-négatives (traitement médicamenteux), Valeur prédictive des tests.
- MESH :
- analyse : Biomarqueurs pharmacologiques, Marqueurs biologiques tumoraux.
- anatomopathologie : Lymphocytes TIL, Tumeurs du sein triple-négatives.
- diagnostic : Tumeurs du sein triple-négatives.
- immunologie : Tumeurs du sein triple-négatives.
- traitement médicamenteux : Tumeurs du sein triple-négatives.
- usage thérapeutique : Anticorps monoclonaux humanisés, Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Finlande, Humains, Pronostic, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Traitement médicamenteux adjuvant, Trastuzumab, Valeur prédictive des tests.
- Wicri :
- geographic : Finlande.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Pharmacological (analysis), Biomarkers, Tumor (analysis), Chemotherapy, Adjuvant, Female, Finland, Humans, Lymphocytes, Tumor-Infiltrating (pathology), Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Trastuzumab, Treatment Outcome, Triple Negative Breast Neoplasms (diagnosis), Triple Negative Breast Neoplasms (drug therapy), Triple Negative Breast Neoplasms (immunology), Triple Negative Breast Neoplasms (pathology).
- MESH :
- chemical , analysis : Biomarkers, Pharmacological, Biomarkers, Tumor.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- geographic : Finland, Trastuzumab.
- diagnosis : Triple Negative Breast Neoplasms.
- drug therapy : Triple Negative Breast Neoplasms.
- immunology : Triple Negative Breast Neoplasms.
- pathology : Lymphocytes, Tumor-Infiltrating, Triple Negative Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Treatment Outcome.
Abstract
We have previously shown the prognostic importance of tumor-infiltrating lymphocytes (TILs) in newly diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+).
DOI: 10.1093/annonc/mdu112
PubMed: 24608200
Affiliations:
- Allemagne, Australie, Belgique, Finlande, France
- Berlin, Région de Bruxelles-Capitale
- Berlin, Bruxelles
- Université libre de Bruxelles
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003546
- to stream PubMed, to step Curation: 003433
- to stream PubMed, to step Checkpoint: 003433
- to stream Ncbi, to step Merge: 001849
- to stream Ncbi, to step Curation: 001849
- to stream Ncbi, to step Checkpoint: 001849
- to stream Main, to step Merge: 003397
- to stream Main, to step Curation: 003385
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.</title><author><name sortKey="Loi, S" sort="Loi, S" uniqKey="Loi S" first="S" last="Loi">S. Loi</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne,Australia sherene.loi@petermac.org.</nlm:affiliation><orgName type="university">Université libre de Bruxelles</orgName><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region type="region" nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université libre de Bruxelles</orgName><placeName><settlement type="city">Bruxelles</settlement><region type="region" nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Salgado, R" sort="Salgado, R" uniqKey="Salgado R" first="R" last="Salgado">R. Salgado</name><affiliation wicri:level="3"><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Anatomical Pathology, Institut Jules Bordet, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Sirtaine, N" sort="Sirtaine, N" uniqKey="Sirtaine N" first="N" last="Sirtaine">N. Sirtaine</name><affiliation wicri:level="3"><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Anatomical Pathology, Institut Jules Bordet, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Jose, V" sort="Jose, V" uniqKey="Jose V" first="V" last="Jose">V. Jose</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Fumagalli, D" sort="Fumagalli, D" uniqKey="Fumagalli D" first="D" last="Fumagalli">D. Fumagalli</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Kellokumpu Lehtinen, P L" sort="Kellokumpu Lehtinen, P L" uniqKey="Kellokumpu Lehtinen P" first="P-L" last="Kellokumpu-Lehtinen">P-L Kellokumpu-Lehtinen</name><affiliation><nlm:affiliation>Department of Oncology, Tampere University Hospital, Tampere.</nlm:affiliation><wicri:noCountry code="subField">Tampere</wicri:noCountry></affiliation></author><author><name sortKey="Bono, P" sort="Bono, P" uniqKey="Bono P" first="P" last="Bono">P. Bono</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation><wicri:noCountry code="subField">Helsinki</wicri:noCountry></affiliation></author><author><name sortKey="Kataja, V" sort="Kataja, V" uniqKey="Kataja V" first="V" last="Kataja">V. Kataja</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Center, Kuopio University Hospital, Kuopio, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Cancer Center, Kuopio University Hospital, Kuopio</wicri:regionArea><wicri:noRegion>Kuopio</wicri:noRegion></affiliation></author><author><name sortKey="Desmedt, C" sort="Desmedt, C" uniqKey="Desmedt C" first="C" last="Desmedt">C. Desmedt</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Piccart, M J" sort="Piccart, M J" uniqKey="Piccart M" first="M J" last="Piccart">M J Piccart</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medicine, Institut Jules Bordet, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name><affiliation><nlm:affiliation>German Breast Group, Neu-Isenburg.</nlm:affiliation><wicri:noCountry code="subField">Neu-Isenburg</wicri:noCountry></affiliation></author><author><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name><affiliation wicri:level="3"><nlm:affiliation>Charité University Hospital, Institute of Pathology, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité University Hospital, Institute of Pathology, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name><affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author><author><name sortKey="Joensuu, H" sort="Joensuu, H" uniqKey="Joensuu H" first="H" last="Joensuu">H. Joensuu</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation><wicri:noCountry code="subField">Helsinki</wicri:noCountry></affiliation></author><author><name sortKey="Sotiriou, C" sort="Sotiriou, C" uniqKey="Sotiriou C" first="C" last="Sotiriou">C. Sotiriou</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24608200</idno><idno type="pmid">24608200</idno><idno type="doi">10.1093/annonc/mdu112</idno><idno type="wicri:Area/PubMed/Corpus">003546</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003546</idno><idno type="wicri:Area/PubMed/Curation">003433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003433</idno><idno type="wicri:Area/PubMed/Checkpoint">003433</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003433</idno><idno type="wicri:Area/Ncbi/Merge">001849</idno><idno type="wicri:Area/Ncbi/Curation">001849</idno><idno type="wicri:Area/Ncbi/Checkpoint">001849</idno><idno type="wicri:Area/Main/Merge">003397</idno><idno type="wicri:Area/Main/Curation">003385</idno><idno type="wicri:Area/Main/Exploration">003385</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.</title><author><name sortKey="Loi, S" sort="Loi, S" uniqKey="Loi S" first="S" last="Loi">S. Loi</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne,Australia sherene.loi@petermac.org.</nlm:affiliation><orgName type="university">Université libre de Bruxelles</orgName><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region type="region" nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université libre de Bruxelles</orgName><placeName><settlement type="city">Bruxelles</settlement><region type="region" nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Salgado, R" sort="Salgado, R" uniqKey="Salgado R" first="R" last="Salgado">R. Salgado</name><affiliation wicri:level="3"><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Anatomical Pathology, Institut Jules Bordet, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Sirtaine, N" sort="Sirtaine, N" uniqKey="Sirtaine N" first="N" last="Sirtaine">N. Sirtaine</name><affiliation wicri:level="3"><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Anatomical Pathology, Institut Jules Bordet, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Jose, V" sort="Jose, V" uniqKey="Jose V" first="V" last="Jose">V. Jose</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Fumagalli, D" sort="Fumagalli, D" uniqKey="Fumagalli D" first="D" last="Fumagalli">D. Fumagalli</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Kellokumpu Lehtinen, P L" sort="Kellokumpu Lehtinen, P L" uniqKey="Kellokumpu Lehtinen P" first="P-L" last="Kellokumpu-Lehtinen">P-L Kellokumpu-Lehtinen</name><affiliation><nlm:affiliation>Department of Oncology, Tampere University Hospital, Tampere.</nlm:affiliation><wicri:noCountry code="subField">Tampere</wicri:noCountry></affiliation></author><author><name sortKey="Bono, P" sort="Bono, P" uniqKey="Bono P" first="P" last="Bono">P. Bono</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation><wicri:noCountry code="subField">Helsinki</wicri:noCountry></affiliation></author><author><name sortKey="Kataja, V" sort="Kataja, V" uniqKey="Kataja V" first="V" last="Kataja">V. Kataja</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Center, Kuopio University Hospital, Kuopio, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Cancer Center, Kuopio University Hospital, Kuopio</wicri:regionArea><wicri:noRegion>Kuopio</wicri:noRegion></affiliation></author><author><name sortKey="Desmedt, C" sort="Desmedt, C" uniqKey="Desmedt C" first="C" last="Desmedt">C. Desmedt</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Piccart, M J" sort="Piccart, M J" uniqKey="Piccart M" first="M J" last="Piccart">M J Piccart</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medicine, Institut Jules Bordet, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name><affiliation><nlm:affiliation>German Breast Group, Neu-Isenburg.</nlm:affiliation><wicri:noCountry code="subField">Neu-Isenburg</wicri:noCountry></affiliation></author><author><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name><affiliation wicri:level="3"><nlm:affiliation>Charité University Hospital, Institute of Pathology, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité University Hospital, Institute of Pathology, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name><affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author><author><name sortKey="Joensuu, H" sort="Joensuu, H" uniqKey="Joensuu H" first="H" last="Joensuu">H. Joensuu</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation><wicri:noCountry code="subField">Helsinki</wicri:noCountry></affiliation></author><author><name sortKey="Sotiriou, C" sort="Sotiriou, C" uniqKey="Sotiriou C" first="C" last="Sotiriou">C. Sotiriou</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers, Pharmacological (analysis)</term><term>Biomarkers, Tumor (analysis)</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Finland</term><term>Humans</term><term>Lymphocytes, Tumor-Infiltrating (pathology)</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Trastuzumab</term><term>Treatment Outcome</term><term>Triple Negative Breast Neoplasms (diagnosis)</term><term>Triple Negative Breast Neoplasms (drug therapy)</term><term>Triple Negative Breast Neoplasms (immunology)</term><term>Triple Negative Breast Neoplasms (pathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Biomarqueurs pharmacologiques (analyse)</term><term>Femelle</term><term>Finlande</term><term>Humains</term><term>Lymphocytes TIL (anatomopathologie)</term><term>Marqueurs biologiques tumoraux (analyse)</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Traitement médicamenteux adjuvant</term><term>Trastuzumab</term><term>Tumeurs du sein triple-négatives (anatomopathologie)</term><term>Tumeurs du sein triple-négatives (diagnostic)</term><term>Tumeurs du sein triple-négatives (immunologie)</term><term>Tumeurs du sein triple-négatives (traitement médicamenteux)</term><term>Valeur prédictive des tests</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Pharmacological</term><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Finland</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Biomarqueurs pharmacologiques</term><term>Marqueurs biologiques tumoraux</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphocytes TIL</term><term>Tumeurs du sein triple-négatives</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein triple-négatives</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Tumeurs du sein triple-négatives</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphocytes, Tumor-Infiltrating</term><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein triple-négatives</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Finlande</term><term>Humains</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Traitement médicamenteux adjuvant</term><term>Trastuzumab</term><term>Valeur prédictive des tests</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Finlande</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have previously shown the prognostic importance of tumor-infiltrating lymphocytes (TILs) in newly diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+).</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Finlande</li><li>France</li></country><region><li>Berlin</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Berlin</li><li>Bruxelles</li></settlement><orgName><li>Université libre de Bruxelles</li></orgName></list><tree><noCountry><name sortKey="Bono, P" sort="Bono, P" uniqKey="Bono P" first="P" last="Bono">P. Bono</name><name sortKey="Joensuu, H" sort="Joensuu, H" uniqKey="Joensuu H" first="H" last="Joensuu">H. Joensuu</name><name sortKey="Kellokumpu Lehtinen, P L" sort="Kellokumpu Lehtinen, P L" uniqKey="Kellokumpu Lehtinen P" first="P-L" last="Kellokumpu-Lehtinen">P-L Kellokumpu-Lehtinen</name><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name></noCountry><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Loi, S" sort="Loi, S" uniqKey="Loi S" first="S" last="Loi">S. Loi</name></region><name sortKey="Desmedt, C" sort="Desmedt, C" uniqKey="Desmedt C" first="C" last="Desmedt">C. Desmedt</name><name sortKey="Fumagalli, D" sort="Fumagalli, D" uniqKey="Fumagalli D" first="D" last="Fumagalli">D. Fumagalli</name><name sortKey="Jose, V" sort="Jose, V" uniqKey="Jose V" first="V" last="Jose">V. Jose</name><name sortKey="Piccart, M J" sort="Piccart, M J" uniqKey="Piccart M" first="M J" last="Piccart">M J Piccart</name><name sortKey="Salgado, R" sort="Salgado, R" uniqKey="Salgado R" first="R" last="Salgado">R. Salgado</name><name sortKey="Sirtaine, N" sort="Sirtaine, N" uniqKey="Sirtaine N" first="N" last="Sirtaine">N. Sirtaine</name><name sortKey="Sotiriou, C" sort="Sotiriou, C" uniqKey="Sotiriou C" first="C" last="Sotiriou">C. Sotiriou</name></country><country name="France"><region name="Région de Bruxelles-Capitale"><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name></region></country><country name="Finlande"><noRegion><name sortKey="Kataja, V" sort="Kataja, V" uniqKey="Kataja V" first="V" last="Kataja">V. Kataja</name></noRegion></country><country name="Allemagne"><region name="Berlin"><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name></region></country><country name="Australie"><noRegion><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003385 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003385 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24608200
|texte= Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24608200" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |